797 related articles for article (PubMed ID: 31858669)
1. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.
Vuorio A; Watts GF; Schneider WJ; Tsimikas S; Kovanen PT
J Intern Med; 2020 Jan; 287(1):2-18. PubMed ID: 31858669
[TBL] [Abstract][Full Text] [Related]
2. Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a).
Vuorio A; Watts GF; Kovanen PT
Eur Heart J; 2017 Dec; 38(48):3555-3559. PubMed ID: 29029165
[TBL] [Abstract][Full Text] [Related]
3. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
Arca M
Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives.
Wu MF; Xu KZ; Guo YG; Yu J; Wu Y; Lin LM
Cardiovasc Drugs Ther; 2019 Dec; 33(6):739-748. PubMed ID: 31655942
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia.
Vuorio A; Watts GF; Kovanen PT
Atherosclerosis; 2019 Feb; 281():25-30. PubMed ID: 30616181
[TBL] [Abstract][Full Text] [Related]
7. Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre.
Mickiewicz A; Borowiec-Wolna J; Bachorski W; Gilis-Malinowska N; Gałąska R; Raczak G; Chmara M; Wasąg B; Jaguszewski MJ; Fijałkowski M; Gruchała M
Cardiol J; 2019; 26(6):669-679. PubMed ID: 30234904
[TBL] [Abstract][Full Text] [Related]
8. Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?
Reiner Ž
Curr Atheroscler Rep; 2019 Mar; 21(4):14. PubMed ID: 30847681
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
[TBL] [Abstract][Full Text] [Related]
10. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein(a): the revenant.
Gencer B; Kronenberg F; Stroes ES; Mach F
Eur Heart J; 2017 May; 38(20):1553-1560. PubMed ID: 28329241
[TBL] [Abstract][Full Text] [Related]
12. Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study.
Sun D; Li S; Zhao X; Wu NQ; Zhu CG; Guo YL; Gao Y; Qing P; Cui CJ; Liu G; Sun J; Dong Q; Li JJ
Metabolism; 2018 Feb; 79():33-41. PubMed ID: 29129821
[TBL] [Abstract][Full Text] [Related]
13. Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN.
Nicholls SJ; Nelson AJ; Ditmarsch M; Kastelein JJP; Ballantyne CM; Ray KK; Navar AM; Nissen SE; Golberg AC; Brunham LR; Curcio D; Wuerdeman E; Neild A; Kling D; Hsieh A; Dicklin MR; Ference BA; Laufs U; Banach M; Mehran R; Catapano AL; Davidson MH
Am Heart J; 2024 Aug; 274():32-45. PubMed ID: 38705341
[TBL] [Abstract][Full Text] [Related]
14. PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a).
Watts GF; Chan DC; Pang J; Ma L; Ying Q; Aggarwal S; Marcovina SM; Barrett PHR
Metabolism; 2020 Jun; 107():154221. PubMed ID: 32240727
[TBL] [Abstract][Full Text] [Related]
15. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
16. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
[TBL] [Abstract][Full Text] [Related]
17. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.
Miname MH; Santos RD
Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498
[TBL] [Abstract][Full Text] [Related]
18. Familial hypercholesterolemia treatments: Guidelines and new therapies.
Raal FJ; Hovingh GK; Catapano AL
Atherosclerosis; 2018 Oct; 277():483-492. PubMed ID: 30270089
[TBL] [Abstract][Full Text] [Related]
19. In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members.
Zawacki AW; Dodge A; Woo KM; Ralphe JC; Peterson AL
J Clin Lipidol; 2018; 12(6):1445-1451. PubMed ID: 30150142
[TBL] [Abstract][Full Text] [Related]
20. Hyperlipoproteinaemia(a) - apheresis and emerging therapies.
Vogt A
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):12-17. PubMed ID: 28185213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
